PMID- 26347512
OWN - NLM
STAT- MEDLINE
DCOM- 20170623
LR  - 20220409
IS  - 2005-1212 (Electronic)
IS  - 1976-2283 (Print)
IS  - 1976-2283 (Linking)
VI  - 10
IP  - 3
DP  - 2016 May 23
TI  - Factors Contributing to the Preference of Korean Patients with Crohn's Disease 
      When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study).
PG  - 391-8
LID - 10.5009/gnl15126 [doi]
AB  - BACKGROUND/AIMS: Two comparable anti-tumor necrosis factor (TNF) agents with 
      different routes of administration (intravenous [iv] infliximab [IFX] vs 
      subcutaneous [sc] adalimumab [ADA]) are available for patients with Crohn's 
      disease (CD) in Korea. This study aimed to identify the preferences of Korean CD 
      patients for a specific anti-TNF agent and the factors contributing to the 
      decision. METHODS: A prospective survey was performed among anti-TNF-naive CD 
      patients in 10 tertiary referral hospitals. A 16-item questionnaire addressed 
      patient preferences and the factors contributing to the decision in favor of a 
      particular anti-TNF agent. A logistic regression was conducted to assess 
      predictive factors for ADA preference. RESULTS: Overall, 189 patients (139 males; 
      mean age, 32.47+/-11.71 years) completed the questionnaire. IFX and ADA were 
      preferred by 63.5% (120/189) and 36.5% (69/189) of patients, respectively. The 
      most influential reason for choosing IFX was 'doctor's presence' (68.3%, 82/120), 
      and ADA was "easy to use" (34.8%, 24/69). Amid various clinicodemographic data, 
      having a >60-minute travel time to the hospital was a significant independent 
      predictive factor for ADA preference. CONCLUSIONS: A large number of 
      anti-TNF-naive Korean patients with CD preferred anti-TNFs with an iv route of 
      administration. The reassuring effect of a doctor's presence might be the main 
      contributing factor for this decision.
FAU - Kim, Eun Soo
AU  - Kim ES
AD  - Department of Internal Medicine, Keimyung University School of Medicine, Daegu, 
      Korea.
FAU - Kim, Kyeong Ok
AU  - Kim KO
AD  - Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, 
      Korea.
FAU - Jang, Byung Ik
AU  - Jang BI
AD  - Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, 
      Korea.
FAU - Lee, Chang Kyun
AU  - Lee CK
AD  - Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, 
      Korea.
FAU - Kim, Hyo Jong
AU  - Kim HJ
AD  - Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, 
      Korea.
FAU - Lee, Kang-Moon
AU  - Lee KM
AD  - Department of Internal Medicine, The Catholic University of Korea College of 
      Medicine, Suwon, Korea.
FAU - Kim, You Sun
AU  - Kim YS
AD  - Department of Internal Medicine, Inje University College of Medicine, Seoul, 
      Korea.
FAU - Eun, Chang Soo
AU  - Eun CS
AD  - Department of Internal Medicine, Hanyang University College of Medicine, Guri, 
      Korea.
FAU - Jung, Sung-Ae
AU  - Jung SA
AD  - Department of Internal Medicine, Ewha Womans University School of Medicine, 
      Seoul, Korea.
FAU - Yang, Suk-Kyun
AU  - Yang SK
AD  - Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, 
      Korea.
FAU - Lee, Jun
AU  - Lee J
AD  - Department of Internal Medicine, Chosun University School of Medicine, Gwangju, 
      Korea.
FAU - Kim, Tae-Oh
AU  - Kim TO
AD  - Department of Internal Medicine, Inje University College of Medicine, Busan, 
      Korea.
FAU - Jung, Yunho
AU  - Jung Y
AD  - Department of Internal Medicine, Soonchunhyang University College of Medicine, 
      Cheonan, Korea.
FAU - Seo, Geom Seog
AU  - Seo GS
AD  - Department of Internal Medicine, Wonkwang University School of Medicine, Iksan, 
      Korea.
FAU - Yoon, Soon Man
AU  - Yoon SM
AD  - Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, 
      Korea.
CN  - IBD Study Group of the Korean Association for the Study of the Intestinal 
      Diseases (KASID)
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - Korea (South)
TA  - Gut Liver
JT  - Gut and liver
JID - 101316452
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Biological Products)
RN  - 0 (Gastrointestinal Agents)
RN  - 0 (TNF protein, human)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
CIN - Gut Liver. 2016 May 23;10 (3):327-9. PMID: 27114431
MH  - Adalimumab/therapeutic use
MH  - Adult
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Biological Products/*therapeutic use
MH  - Crohn Disease/*drug therapy/psychology
MH  - Cross-Sectional Studies
MH  - Female
MH  - Gastrointestinal Agents/*therapeutic use
MH  - Humans
MH  - Infliximab/therapeutic use
MH  - Infusions, Intravenous
MH  - Injections, Subcutaneous
MH  - Male
MH  - Patient Preference/*psychology
MH  - Prospective Studies
MH  - Republic of Korea
MH  - Surveys and Questionnaires
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
PMC - PMC4849692
OTO - NOTNLM
OT  - Adalimumab
OT  - Crohn disease
OT  - Infliximab
OT  - Preference
EDAT- 2015/09/09 06:00
MHDA- 2017/06/24 06:00
PMCR- 2016/05/01
CRDT- 2015/09/09 06:00
PHST- 2015/09/09 06:00 [entrez]
PHST- 2015/09/09 06:00 [pubmed]
PHST- 2017/06/24 06:00 [medline]
PHST- 2016/05/01 00:00 [pmc-release]
AID - gnl15126 [pii]
AID - gnl-10-391 [pii]
AID - 10.5009/gnl15126 [doi]
PST - ppublish
SO  - Gut Liver. 2016 May 23;10(3):391-8. doi: 10.5009/gnl15126.